ATE191921T1 - Reinigung von cytokeratinfragmenten - Google Patents

Reinigung von cytokeratinfragmenten

Info

Publication number
ATE191921T1
ATE191921T1 AT91917180T AT91917180T ATE191921T1 AT E191921 T1 ATE191921 T1 AT E191921T1 AT 91917180 T AT91917180 T AT 91917180T AT 91917180 T AT91917180 T AT 91917180T AT E191921 T1 ATE191921 T1 AT E191921T1
Authority
AT
Austria
Prior art keywords
pct
fragments
cytokeratins
cytokeratin
antibodies
Prior art date
Application number
AT91917180T
Other languages
English (en)
Inventor
Ake Silen
Bo Wiklund
Original Assignee
Idl Immunodeveloplab Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idl Immunodeveloplab Ab filed Critical Idl Immunodeveloplab Ab
Application granted granted Critical
Publication of ATE191921T1 publication Critical patent/ATE191921T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT91917180T 1990-09-24 1991-09-24 Reinigung von cytokeratinfragmenten ATE191921T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9003025A SE470273B (sv) 1990-09-24 1990-09-24 Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer
PCT/SE1991/000638 WO1992005197A1 (en) 1990-09-24 1991-09-24 Purification of cytokeratin fragments

Publications (1)

Publication Number Publication Date
ATE191921T1 true ATE191921T1 (de) 2000-05-15

Family

ID=20380430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91917180T ATE191921T1 (de) 1990-09-24 1991-09-24 Reinigung von cytokeratinfragmenten

Country Status (8)

Country Link
US (2) US5728537A (de)
EP (1) EP0550561B1 (de)
JP (1) JP3210666B2 (de)
AT (1) ATE191921T1 (de)
AU (1) AU8546391A (de)
DE (1) DE69132122T2 (de)
SE (1) SE470273B (de)
WO (1) WO1992005197A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
ES2116906B1 (es) * 1996-03-28 1999-03-01 Consejo Superior Investigacion Anticuerpo monocional pc2.27 asociado a tumores.
US6890311B2 (en) 1997-09-16 2005-05-10 The Regents Of The University Of California Methods for performing medical procedures within a breast duct
US6168779B1 (en) * 1997-09-16 2001-01-02 The Regents Of The University Of California Methods and kits for identifying ductal orifices
WO1999016789A1 (en) * 1997-09-30 1999-04-08 Peviva Ab Apoptosis-related compounds and their use
ES2274781T3 (es) * 1999-04-13 2007-06-01 Wilex Ag Empleo diagnostico y terapeutico de anticuerpos contra el receptor de la urocinasa.
US20020122791A1 (en) * 2000-12-21 2002-09-05 Nicolette Charles A. Antigenic CK-18 compounds for therapy and diagnosis and methods for using same
DE10130985B4 (de) * 2001-06-27 2004-03-18 B.R.A.H.M.S Ag Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente
US20030138425A1 (en) * 2001-09-21 2003-07-24 Mather Jennie Powell Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US7306919B1 (en) * 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
AU2003207459A1 (en) * 2002-01-03 2003-07-24 The Scripps Research Institute Cancer-associated epitope
EP1698899A4 (de) * 2003-10-30 2007-05-23 Sysmex Corp Diagnostikum für uterusdrüsenkrebs und verfahren zum nachweis einer drüsenkrebszelle
EP2041299A4 (de) * 2006-07-14 2010-01-13 Aviva Biosciences Corp Verfahren und zusammensetzungen für den nachweis seltener zellen aus einer biologischen probe
KR101292163B1 (ko) 2010-11-23 2013-08-12 한양대학교 산학협력단 Ｋｒｔ１９ 항체를 포함하는 항암용 조성물
SE538211C2 (sv) * 2013-04-05 2016-04-05 Idl Biotech Ab Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2723203B2 (ja) * 1984-01-06 1998-03-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア サイトケラチン腫瘍マーカー及びそれらの検出のためのアッセイ
US4727021A (en) * 1984-06-01 1988-02-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cytokeratin
US4722895A (en) * 1984-09-25 1988-02-02 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Synthetic peptides for the production of specific keratin protein antibodies
DE3815932A1 (de) * 1988-01-26 1989-08-03 Progen Biotechnik Gmbh Verfahren zur identifizierung des ursprungs einer zellgewebsprobe
EP0267355B1 (de) * 1986-11-10 1991-09-18 PROGEN Biotechnik GmbH Verfahren zum Identifizieren gewebstypischer, unlöslicher Cytoskelettproteine
LU86654A1 (de) * 1986-11-10 1988-06-13 Progen Biotechnik Gmbh Verfahren und vorrichtung zum auffinden von zellaesionen
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados

Also Published As

Publication number Publication date
JPH06501469A (ja) 1994-02-17
DE69132122T2 (de) 2001-01-11
US5728537A (en) 1998-03-17
EP0550561B1 (de) 2000-04-19
SE9003025D0 (sv) 1990-09-24
DE69132122D1 (de) 2000-05-25
AU8546391A (en) 1992-04-15
EP0550561A1 (de) 1993-07-14
JP3210666B2 (ja) 2001-09-17
SE470273B (sv) 1993-12-20
WO1992005197A1 (en) 1992-04-02
US5780032A (en) 1998-07-14
SE9003025L (sv) 1992-03-25

Similar Documents

Publication Publication Date Title
ATE191921T1 (de) Reinigung von cytokeratinfragmenten
AU1518795A (en) Immunoassays for prostate specific antigen
GB2128630A (en) Method of affinity purification employing monoclonal antibodies
CA2047717A1 (en) Monoclonal antibodies for small moieties, methods therefor
DE69228701D1 (de) Fragmente von Prion Proteinen.
EP0597829A4 (de) Monoklonaler antikörper gegen einen neuen mit menschlichen tumoren assoziierten antigen.
ES2143489T3 (es) Mejoras en radioetiquetado.
DE59308000D1 (de) Immunoassay zum nachweis von kollagen oder kollagenfragmenten
FI922017A0 (fi) Immunbestaemningar och monoklonala antikroppar foer protrombinaktiveringspeptider och degradations- produkter av dessa.
ATE128986T1 (de) Antigen sf-25 des darm-adenokarzinoms sowie antikörper, die dieses antigen erkennen.
SE8403630L (sv) Humana proteiner
DE3854999D1 (de) An karzinoma assoziierte antigene und antikörper, die diese antigene erkennen
ATE116004T1 (de) Antikörper gegen menschliches sperma, ihre herstellung und anwendung.
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
DE59010723D1 (de) Verwendung kohlenwasserstoffreicher Gele als Fracturing-Flüssigkeiten
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
ATE130200T1 (de) Neue verwendung für einen monoklonalen antikörper.
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
ES276247U (es) Gafa de cristales intercambiables
IL68364A0 (en) Ethosuximide immunogens,antibodies prepared therefrom,labeled ethosuximide conjugates and related derivatives and the use of such antibodies and labeled conjugates in immunoassays
CA2178504A1 (en) Immunoassays for prostate specific antigen
ES477409A1 (es) Un metodo para la fabricacion de lentes de contacto blandas.
GR890100333A (en) Antihuman antigen antibodies

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee